TMEM106B is associated with frontotemporal lobar degeneration in a clinically diagnosed patient cohort by van der Zee, Julie et al.
BRAIN
A JOURNAL OF NEUROLOGY
TMEM106B is associated with frontotemporal
lobar degeneration in a clinically diagnosed
patient cohort
Julie van der Zee,
1,2 Tim Van Langenhove,
1,2 Gernot Kleinberger,
1,2 Kristel Sleegers,
1,2
Sebastiaan Engelborghs,
2,3,4 Rik Vandenberghe,
5 Patrick Santens,
6 Marleen Van den Broeck,
1,2
Geert Joris,
1,2 Jolien Brys,
1,2 Maria Mattheijssens,
1,2 Karin Peeters,
1,2 Patrick Cras,
2,7
Peter P. De Deyn,
2,3,4 Marc Cruts
1,2 and Christine Van Broeckhoven
1,2
1 Neurodegenerative Brain Diseases Group, VIB Department of Molecular Genetics, Universiteitsplein 1, 2610 Antwerpen, Belgium
2 Institute Born-Bunge, University of Antwerp, Universiteitsplein 1, 2610 Antwerpen, Belgium
3 Department of Neurology, Hospital Network Antwerp (ZNA) Middelheim, Lindendreef 1, 2020 Antwerpen, Belgium
4 Memory Clinic, Hospital Network Antwerp (ZNA) Hoge Beuken, Commandant Weynsstraat 165, 2660 Hoboken, Belgium
5 Department of Neurology, University Hospitals Leuven and University of Leuven (KULeuven), Campus Gasthuisberg, Herestraat 49, 3000 Leuven,
Belgium
6 Department of Neurology, University Hospital Ghent and Ghent University, De Pintelaan 185, 9000 Gent, Belgium
7 Department of Neurology, University Hospital Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium
Correspondence to: Prof. Dr Christine Van Broeckhoven,
Neurodegenerative Brain Disease Group,
VIB Department of Molecular Genetics,
University of Antwerp – CDE,
Universiteitsplein 1,
2610 Antwerpen, Belgium
E-mail: christine.vanbroeckhoven@molgen.vib-ua.be
In a genome-wide association study of frontotemporal lobar degeneration with pathological inclusions of TAR DNA-binding
protein, signiﬁcant association was obtained with three single nucleotide polymorphisms at 7p21.3, in a region encompassing
the gene TMEM106B. This study also suggested a potential modifying effect of TMEM106B on disease since the association
was strongest in progranulin mutation carriers. Further, the risk effect seemed to correlate with increased TMEM106B expression
in patients. In the present study, we sought to replicate these three ﬁndings using an independent Flanders–Belgian cohort of
primarily clinically diagnosed patients with frontotemporal lobar degeneration (n = 288). We were able to conﬁrm the associ-
ation with TMEM106B with a P-value of 0.008 for rs1990622, the top marker from the genome-wide association study [odds
ratio 0.75 (95% conﬁdence interval 0.61–0.93)]. Further, high-density single nucleotide polymorphism mapping suggested that
the association was solely driven by the gene TMEM106B. Homozygous carriers of the TMEM106B protective alleles had a 50%
reduced risk of developing frontotemporal lobar degeneration. However, we were unable to detect a modifying effect of the
TMEM106B single nucleotide polymorphisms on onset age in progranulin mutation carriers belonging to an extended, clinical
and pathological well-documented founder family segregating a progranulin null mutation. Also, we could not observe signiﬁ-
cant differences in messenger RNA expression between patients and control individuals in lymphoblast cell lines and in brain
frontal cortex. In conclusion, we replicated the genetic TMEM106B association in a primarily clinically diagnosed cohort of
patients with frontotemporal lobar degeneration from Flanders–Belgium. Additional studies are needed to unravel the molecular
role of TMEM106B in disease onset and pathogenesis.
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Introduction
Since frontotemporal lobar degeneration (FTLD) was linked to
chromosome 17, enormous progress has been made in the mo-
lecular genetics and neuropathology of FTLD providing valuable
insights into its disease pathogenesis. However, yet the underlying
disease mechanisms of FTLD are not fully understood and no ef-
fective treatments are available. Two major pathological subtypes
exist i.e. FTLD with cellular inclusion bodies of tau (FTLD-tau) or
TDP-43 (FTLD-TDP), each representing 40–50% of patients
(Mackenzie et al., 2010). Whereas pathogenic mutations in the
gene coding for the microtubule associated protein tau (MAPT)
is associated with FTLD-tau, FTLD-TDP pathology is observed in
patients carrying a mutation in progranulin (GRN) or in the
valosin-containing protein gene (VCP) (Mackenzie et al., 2010).
An international collaborative genome-wide association study,
aimed at identifying genetic risk factors inﬂuencing FTLD-TDP
pathology, was performed in patients with either autopsy con-
ﬁrmed FTLD-TDP or a clinical diagnosis of FTLD in the presence
of a GRN mutation (Van Deerlin et al., 2010). Three single nu-
cleotide polymorphisms (SNPs) reached genome-wide signiﬁcance
(rs1020004, rs6966915 and rs1990622) and mapped to a single
linkage disequilibrium block of 68kb at 7p21.3. The genomic
region encompassed the gene coding for TMEM106B, an unchar-
acterized transmembrane protein, and two other genes at the rim
of the linked region, scinderin (SCIN) and ADP-ribosylation
factor-like 4A (ARL4A). The effect appeared to be most pro-
nounced in carriers of pathogenic GRN mutations, suggesting a
modifying effect of TMEM106B in GRN mutation carriers.
Furthermore, messenger RNA quantiﬁcations showed 42.5-fold
increased TMEM106B expression in frontal cortex of patients
with FTLD-TDP compared with unaffected individuals. These ﬁnd-
ings suggested that the increased TMEM106B expression in brain
could be linked to FTLD-TDP pathogenesis, however, they were
based on a modest number of brain samples (n = 25).
It is commonly accepted that newly identiﬁed risk genes, such
as those identiﬁed in genome-wide association studies of complex
diseases, can only be established if they are replicated in inde-
pendent study populations. Therefore, we set out to replicate
the FTLD association with the TMEM106B locus in a Flanders–
Belgian cohort of patients and control individuals. In contrast
to the original study, which selected patients with FTLD-TDP
pathology, we used a selection of patients with primarily clinical
diagnoses of FTLD.
Materials and methods
Study cohorts
Patients with FTLD included in this study were recruited from 1998
onwards in Flanders–Belgium as part of an ongoing collaboration of
neurology departments and memory clinics of the Hospital Network
Antwerp (ZNA) Middelheim and ZNA Hoge Beuken, the University
Hospital Antwerp, the University Hospitals Leuven and the University
Hospital Ghent. All index patients were evaluated using a standard
diagnostic protocol including neurological examination, neuropsycho-
logical testing, biochemical analyses, EEG and neuroimaging. Clinical
diagnosis was made according the Neary consensus criteria for FTLD
(Neary et al., 1998, 2005) and patients were followed longitudinally
on a regular basis. Plasma, serum and cerebrospinal ﬂuid samples
were collected. In a subset of patients, neuropathological examination
of autopsied brain was performed to obtain diagnostic certainty and
to deﬁne the FTLD pathology subtype (Engelborghs et al., 2008).
Index patients collected in the clinics as well as patients who were
referred for genetic testing to our diagnostic service facility, were con-
tacted to obtain consented participation in molecular genetic studies of
neurodegenerative dementias. Blood samples from patients, their rela-
tives and from control individuals were collected for DNA extraction,
establishing Epstein-Barr virus transformed lymphoblast cell lines and
the collection of serum and plasma. Neurologically healthy community
control individuals were ascertained in Flanders–Belgium and under-
went a medical interview questioning their personal, medical and
family history of neurological or psychiatric disease followed by a
mini-mental state examination. Brain autopsy and pathological testing
was proposed to patients and/or their legal guardians as well as to
control individuals.
All participants gave written informed consent for participation in
both the clinical and genetic studies. The clinical study protocol and
the informed consent forms for patient ascertainment were approved
by the Medical Ethic Committees of ZNA Middelheim and ZNA Hoge
Beuken, University Hospital Antwerp, University Hospitals Leuven and
University Hospital Ghent. The genetic study protocol and informed
consent forms were approved by the Medical Ethical Committee,
University of Antwerp, Belgium. Patient relatives and control individ-
uals were ascertained after written informed consent, within the frame
of the medical ethical approved genetic study protocol. All samples
received a unique identiﬁer number and demographic, medical and
genetic data were stored in a centralized database. Restrictive access
permissions were given to researchers and clinicians depending on
their respective role in the study.
Study subjects
From the Flanders–Belgian FTLD study population of 315 patients,
297 unrelated patients with a clinical diagnosis of FTLD were selected
for the purpose of this study (Table 1). All patients were analysed
for mutations in the four FTLD genes—MAPT, GRN, VCP and
CHMP2B (Hutton et al., 1998; Watts et al., 2004; Skibinski et al.,
2005; Baker et al., 2006; Cruts et al., 2006). We excluded patients
with known non-TDP pathology, patients carrying a mutation in
MAPT or CHMP2B (van der Zee et al., 2008) or having an autopsy
diagnosis other than FTLD-TDP. The ﬁnal FTLD patient cohort counted
13 unrelated patients carrying a GRN loss-of-function mutation includ-
ing one patient of the GRN IVS1 + 5G4C founder family (Cruts
et al., 2006; Gijselinck et al., 2008), and two unrelated patients
with the VCP R159H mutation (van der Zee et al., 2009). Twenty-
two patients had a clinical diagnosis of FTLD with amyotrophic lateral
sclerosis, and 14 patients had a pathology diagnosis of FTLD-TDP.
Average onset age was 62.8   10.7 years and ranged from 29 to
90 years. At least one other affected relative was reported in 33.7%
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original FTLD-TDP genome-wide association study (Van Deerlin et al.,
2010) and were excluded from the replication analysis. After we con-
ﬁrmed association of TMEM106B with FTLD in our Flanders–Belgian
cohort, we included all 297 patients in the SNP ﬁne-mapping. To
maximize the power to ﬁnd disease association, we used a control
population twice the size of the patient sample. The 595 age-matched
control individuals had an average age at inclusion of 61.8   15.4
years ranging from 19–94 years (Table 1). Only disease-free individ-
uals without family history of neurodegenerative brain diseases and a
mini-mental state examination score424 were included in the control
sample. Together this patient–control cohort offered499% power to
detect disease association of a variant with minor allele frequency of
0.4 and odds ratio of 0.6 [values based on the ﬁndings of Van Deerlin
et al. (2010), calculated with the Genetic Power Calculator (Purcell
et al., 2003)].
Age at onset analysis was also performed in the Flanders–Belgian
GRN founder family, an extended FTLD pedigree segregating the GRN
IVS1 + 5G4C null mutation and in which a wide range in onset age
was previously reported (Cruts et al., 2006; Brouwers et al., 2007).
The founder pedigree consists of 10 branches containing 226 clinically
documented individuals, including 41 patients with FTLD and 37 cog-
nitively healthy mutation carriers. Onset age in the patients varied
between 45 and 76 years (63.2   7.4 years). One in four mutation
carriers was still cognitively intact at age 460 years and three obligate
mutation carriers died without clinical signs of FTLD at ages 69,
74 and 81 years. DNA was available for 119 individuals, of whom
21 were patients and 29 unaffected mutation carriers.
Sequencing analysis
Genomic DNA was extracted from whole blood by automated DNA
extraction on a Magtration 12GC PLUS (Precision System Science Co.
Ltd, Woerrstadt, Germany). Primers for polymerase chain reaction
ampliﬁcation of genomic DNA and sequencing were designed using
ExonPrimer (accessible through the USCS Genome Browser, http://
genome.ucsc.edu/, primer sequences will be made available on re-
quest). The seven TMEM106B coding exons and non-coding 50- and
30-untranslated regions were analysed. Polymerase chain reaction
amplicons were puriﬁed using the ExoSAP-IT kit (USB Corporation,
Cleveland, OH, USA) and sequenced using the BigDye Terminator
Cycle Sequencing kit v3.1 (Applied Biosystems, Foster City, CA, USA)
on an ABI3730 automated sequencer (Applied Biosystems). Sequence
variations were detected using the software package novoSNP (Weckx
et al., 2005) and conﬁrmed by visual inspection of the DNA sequence
traces. The online software tools PMUT (Ferrer-Costa et al., 2005) and
FastSNP (Yuan et al., 2006) were used to predict the effect of amino
acid substitutions on protein function.
SNP selection and genotyping
To reconstruct the linkage disequilibrium structure in the Flanders–
Belgian population, we genotyped 39 SNPs in the control cohort.
SNPs were selected from the HapMap2 CEU data and from the
common variants detected by sequencing, and were checked for de-
viations of Hardy-Weinberg equilibrium. For association ﬁne-mapping,
nine tag SNPs were selected from within the 36kb linkage disequilib-
rium block around TMEM106B plus seven SNPs up- and down-
stream of the linkage disequilibrium block. SNPs from the HapMap2
CEU data were selected by the pair-wise tagging method with an
r
240.8, minor allele frequency 45% and call rate 475%, and
complemented by three independent sequencing SNPs to capture
the complete genetic variability across the linkage disequilibrium
block in the Flanders–Belgian population. All SNPs were genotyped
by Sequenom MassArray technology (Sequenom Inc., Hamburg,
Germany). Polymerase chain reaction and extension primers were
designed using the Assay Design 3.0 Software (Sequenom Inc.,
primer sequences will be made available on request). Genotypes
were assigned using the TyperAnalyser 4.0 programme (Sequenom
Inc.) and checked by visual inspection.
Statistical analyses
With the statistical analysis programme PLINK version 1.07 (Purcell
et al., 2007) allelic and genotypic associations were calculated using
logistic regression under an additive model taking into account age
and gender (age of onset for patients, age at inclusion for control
individuals; disease status was set as the dependent variable and geno-
type as independent variable, age and gender were used as covari-
ables). Onset age analysis for rs10200004 and rs1990622 in the total
FTLD patient population was performed by univariate analysis of
variances within Statistical Package for the Social Sciences 16.0
Table 1 Description of the Flanders–Belgian FTLD patient and control cohort
Parameters Flanders-Belgian
FTLD cohort
FTLD patient
selection for
current study
Flanders–Belgian
control cohort
Control individual
selection for
current study
N 315 297
c 870 595
Age at onset/inclusion
a 62.3   10.6 (29–90) 62.8   10.7 (29–90) 65.2   14.9 (19–94) 61.8   15.4 (19–94)
Familial
b, n (%) 119 (37.7%) 100 (33.7) NA NA
Mutations, n (%) 30 (9.5) 15 (5.1) NA NA
Pathology diagnoses, n (%) 22 (7.0) 14 (4.7) NA NA
Mutations in the Flanders–Belgian FTLD cohort: 22 GRN (7.0%), 4 MAPT (1.3%), 2 VCP (0.6%), 1 CHMP2B (0.3%) and 1 PSEN1 (0.3%).
Pathology diagnoses in the Flanders–Belgian FTLD cohort: 19 FTLD-TDP (6.0%), 1 FTLD-tau (0.3%), 1 FTLD-UPS (0.3%), 1 FTLD-ni (0.3%).
a Age at onset for patients or age at inclusion for control individuals is shown as the mean   SD (years).
b Familial indicates the number of patients who are known to have at least one other relative with a similar dementia syndrome.
c Nine of the 297 patients were part of the original FTLD-TDP GWA study (Van Deerlin et al., 2010) and were excluded from the replication analysis.
FTLD-TDP = FTLD pathology with TAR DNA-binding protein inclusions; FTLD-tau = FTLD pathology with MAPT protein inclusion; FTLD-UPS = FTLD pathology with
protein inclusions from the ubiquitin proteasome system; FTLD-ni = FTLD pathology with no inclusions of aggregated proteins. NA = not applicable.
For more information on the pathological subtypes of FTLD see Mackenzie et al., 2010.
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family, effect on onset age was estimated in a linkage analysis for cen-
sored quantitative traits using a reversible jump Markov chain Monte
Carlo algorithm implemented in Loki (Heath, 1997), allowing maximal
incorporation of genetic and phenotypic information on all affected and
unaffected mutation carriers. Genotype at rs1020004 or rs1990622 for
the 21 patients and 29 unaffected carriers was entered in the trait
model as a ﬁxed major gene covariate (Wijsman and Yu, 2004).
Gene expression studies
Gene expression analyses were performed in lymphoblast cell lines and
brain frontal cortex.
Lymphoblast cell lines from 22 patients and 26 control individuals
selected from the Flanders patient–control cohort were analysed.
Included in the patient selection were 14 patients with known FTLD-
TDP pathology of which nine were GRN and two were VCP mutation
carriers, and eight patients had unknown underlying FTLD pathology.
Brain frontal cortex samples were obtained from 11 patients with
FTLD-TDP including two GRN and three VCP mutation carriers,
together with 12 control individuals.
For brain samples, 30–50mg of fresh-frozen frontal cortex was
ground in liquid nitrogen for RNA extraction. Total RNA was extracted
using the Ribopure
TM
kit (Ambion, Applied Biosystems) and treated
with DNase (Turbo
TM
DNase Kit; Ambion, Applied Biosystems).
RNA quality was veriﬁed on an Agilent 2100 Bioanalyser using the
RNA 6000 pico kit (Agilent, Diegm, Belgium) and only samples were
included with a RNA integrity number 45.8 (Supplementary Table 3).
First strand complementary DNA was synthesized with random
hexamer primers using SuperScript III First-Strand Synthesis System
(Invitrogen, Carlsbad, CA, USA). Gene expression was analysed
by quantitative reverse-transcription polymerase chain reaction.
Ampliﬁcation was carried out for 40 cycles with TMEM106B speciﬁc
forward and reverse primers (primer sequences will be made available
on request) on an ABI 7900HT instrument (Applied Biosystems) using
a SYBR Green I mastermix (Applied Biosystems). Messenger RNA
levels were quantiﬁed using the delta–delta CT method and normalized
to the geometric mean of the two most stable housekeeping genes
(GAPDH and ACTB) from a set of four tested housekeeping genes
(GAPDH, SDHA, PPIA and ACTB) as determined by the algorithm
GeNorm (Vandesompele et al., 2002). Quantitative reverse-
transcription polymerase chain reaction analyses were performed at
least in duplicate and each run was followed by a melting curve ana-
lysis to ensure that only one product was formed at the expected
melting temperature. Differences in TMEM106B expression were ana-
lysed by non-parametric Kruskal–Wallis test for the comparison of
three groups and Mann–Whitney U-test for two group comparisons.
Results
Replication of TMEM106B locus
association
The ﬁrst aim in our study was to replicate association with the three
genome-wide associated SNPs at 7p21.3 in an independent sample
of primarily clinical diagnosed FTLD patients (n = 288) and control
individuals (n=595), ascertained in Flanders–Belgium. Allelic asso-
ciation reached signiﬁcant values of P = 0.008, 0.013 and 0.041
for rs1990622, rs6966915 and rs1020004, respectively (Table 2).
For rs1990622, showing the strongest association, the odds ratio
for the minor C-allele was 0.75 (95% conﬁdence interval 0.61–
0.93), which corresponds to an increased risk associated with the
common allele of 1.33. This positive replication validated further
in-depth analyses of TMEM106B as a novel risk factor for FTLD.
Sequencing analysis
To map the genetic variability at the TMEM106B locus and to look
for potential pathogenic mutations, we sequenced all coding
exons, 30- and 50-untranslated region exons and  100bps of ad-
jacent intronic regions. Direct sequencing revealed a total of 61
variations, 40 common SNPs with a minor allele frequency 40.05
(Supplementary Table 1) and 21 rare SNPs (minor allele frequency
40.05, Supplementary Table 2). Two SNPs predicted amino acid
substitutions, S134N and T185S. S134N is located in exon 5 and
was detected with equal frequencies of 2% in patients as in con-
trol individuals (P = 0.601). T185S or rs3173615 is located in exon
6, and was observed with a frequency of 35% in patients and
42% in control individuals (P = 0.003). Of the remaining SNPs,
none were predicted to be near splice-sites, transcription factor
binding sites, or microRNA binding sites (UCSC Genome
Browser). Considering the results of the mutation analysis, it ap-
pears that TMEM106B does not bear highly penetrant mutations
associated with FTLD in our patient cohort.
Association ﬁne-mapping
The linkage disequilibrium pattern in the European and in our
Flanders–Belgian population delineated a 36kb linkage disequilib-
rium block containing only the gene TMEM106B (Fig. 1). Nine tag
SNPs were selected from within the linkage disequilibrium block to
capture its complete genetic variability in the Flanders–Belgian
population. In addition, four independent SNPs were chosen up-
stream and three downstream of the linkage disequilibrium block
for further association testing in the 297 patients with FTLD and
595 control individuals.
Single-SNP allelic association testing achieved signiﬁcant
P-values (P50.05) for the replicated genome-wide association
Table 2 Allelic association of the FTLD-TDP genome-wide
association study SNPs at the TMEM106B locus in the
Flanders–Belgian FTLD cohort
dbSNP ID Minor
allele
Minor allele
frequency
HWE OR (95% CI) P-value
Patients Controls
rs1020004 C 0.26 0.31 0.44 0.79 (0.63–0.99) 0.041
rs6966915 T 0.35 0.42 1.00 0.77 (0.62–0.95) 0.013
rs1990622 C 0.35 0.42 1.00 0.75 (0.61–0.93) 0.008
SNPs are listed according to their genomic order on chromosome 7. Minor allele
frequencies are given for 288 patients not previously included in the original
genome-wide association study (Van Deerlin et al., 2010) and for 595 control
individuals. P-values and odds ratio (OR) with associated 95% conﬁdence interval
(CI) were calculated under an additive model using logistic regression models
adjusted for age and gender.
HWE = P-value for the test of Hardy–Weinberg equilibrium in control individuals.
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disequilibrium block (Table 3, minimum P-value of 0.003 for
rs1990622). After calculation of genotype frequencies and asso-
ciated effect sizes, only the two genome-wide association study
SNPs rs1020004 and rs1990622, sustained signiﬁcance (Table 4).
A minimal odds ratio was calculated for rs1020004 [odds
ratioCC = 0.49, (95% conﬁdence interval = 0.27–0.87), P = 0.014].
For rs1990622, one copy of the risk allele was sufﬁcient to achieve a
signiﬁcantly decreased risk effect [odds ratioCT = 0.69, (95% conﬁ-
dence interval 0.51–0.93), P = 0.017; odds ratioCC = 0.55, (95%
conﬁdence interval 0.36–0.86), P = 0.009]. In the Flanders–Belgian
population, correlation between rs1020004 and rs1990622
was 79%.
SNP rs1990622 tags 27 additional markers with a high degree
of linkage disequilibrium (r
2 range 0.93–1). These 27 SNPs include
the third SNP from the genome-wide association study,
rs6966915, but also rs3173615, which is the non-synonymous
SNP coding for T185S that we observed in the sequencing
analysis. SNP rs1020004 captures three more SNPs (r
2 of 1, 1
and 0.88).
Table 3 Allelic association of tag SNPs at the TMEM106B locus in the Flanders–Belgian FTLD cohort
dbSNP ID Minor allele Minor allele frequency HWE OR (95% CI) P-value
Patients Controls
rs4719302 G 0.49 0.46 0.673 – ns
rs13244354 C 0.10 0.12 0.564 ns
rs17165706 T 0.24 0.22 1.000 – ns
rs1435528 G 0.34 0.32 0.153 – ns
rs1865567 G 0.16 0.21 1.00 0.74 (0.55–0.99) 0.039
rs1020004 C 0.26 0.31 0.44 0.77 (0.62–0.97) 0.024
rs17165746 A 0.08 0.1 0.495 – ns
rs13234238 C 0.08 0.09 0.313 – ns
rs1047601 T 0.16 0.13 0.85 – ns
rs10488192 T 0.16 0.19 0.682 – ns
rs1990622 C 0.35 0.42 1.00 0.73 (0.59–0.90) 0.003
rs1548882 C 0.5 0.47 0.352 – ns
rs6945902 A 0.2 0.21 0.219 – ns
rs6952078 T 0.09 0.11 0.397 – ns
rs11977828 T 0.26 0.26 0.387 – ns
rs7457114 A 0.26 0.23 0.403 – ns
SNPs are listed according to their genomic order on chromosome 7. SNPs from Row 5 to Row 13 correspond to the nine tag SNPs located within the 36kb linkage
disequilibrium block. SNPs in bold are the replicated tag SNPs from the FTLD-TDP genome-wide association study (Van Deerlin et al., 2010). Minor allele frequencies in 297
patients and 595 control individuals are given. P-values and odds ratio (OR) with associated 95% conﬁdence interval (CI) were calculated under an additive model using
logistic regression models adjusted for age and gender. Results for SNPs with signiﬁcant P50.05 are listed.
HWE = P-value for the test of Hardy–Weinberg equilibrium in control individuals; ns = not signiﬁcant.
Figure 1 Linkage disequilibrium pattern at the TMEM106B locus. Linkage disequilibrium plot for Hapmap2 CEU data, D0/LOD colour
scheme, interval 12.200–12.270kb. The linkage disequilibrium structure delineates a 36kb block including only the TMEM106B gene.
The relative position of the three replicated SNPs from the genome-wide association study are indicated by ‘X’.
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Analysis of onset age correlation in the Flanders–Belgian FTLD
cohort did not demonstrate an effect of rs1020004 or
rs1990622. Mean difference in onset ages between carriers of
the CT genotype (one copy of the protective allele) and TT geno-
type was  2.5 years for rs1020004 (P = 0.08) and  2.0 years for
rs1990622 (P = 0.171). Mean differences in onset ages between
carriers of the CC genotype (two copies of the protective allele)
and TT genotype was  1.8 years for rs1020004 (P = 0.53) and
 0.3 years for rs1990622 (P = 0.88). Likewise in the Flanders–
Belgian GRN IVS1 + 5G4C founder family, the TMEM106B
SNPs could not explain the observed wide range in onset age in
GRN mutation carriers. Mean difference in onset ages between CT
and TT genotype carriers was  0.39 years for rs1020004
(P = 0.40, minor allele frequency = 0.23), and 1.9 years for
rs1990622 (P = 0.20, minor allele frequency = 0.30). Mean differ-
ence in onset ages between CC and TT genotype carriers was 1.0
years for rs1020004 (P = 0.50) and  0.6 years for rs1990622
(P = 0.50).
Gene expression studies
Correlation of TMEM106B messenger RNA expression with
rs1990622 and disease status was evaluated in lymphoblast
cell lines and brain frontal cortex (Fig. 2). In lymphoblasts, quan-
tiﬁcation of TMEM106B messenger RNA levels in patients demon-
strated no differential expression compared with control
individuals (P = 0.508, Fig. 2A). To evaluate a possible effect
of rs1990622 genotype, data of patients and control individuals
were pooled to maximize the sample size and analysed per geno-
type group; however, comparison of expression yielded no signiﬁ-
cant correlation (PCC versus CT versus TT = 0.484, Fig. 2B). In patients
only or controls only, correlation with genotype was also negative
(data not shown). Similarly, in brain frontal cortex, we did not
observe increased TMEM106B expression. Mean messenger RNA
levels in patients with FTLD-TDP (n=11) was comparable to that
in control individuals (n=12, P = 0.806) as were the levels in the
two genotype groups (PCT versus TT = 0.841, no high quality brain
RNA samples were available for CC carriers).
Discussion
We performed a replication study of the TMEM106B genome-
wide association in FTLD-TDP. Whereas the original genome-
wide association study exclusively included patients with autopsy
conﬁrmed TDP pathology or with a GRN mutation with predicted
TDP pathology (Van Deerlin et al., 2010), our cohort consisted of
patients with primarily clinically diagnosed FTLD. To minimize gen-
etic heterogeneity, we excluded autopsy conﬁrmed patients with-
out TDP pathology and patients carrying a MAPT or CHMP2B
mutation, which are known as non-TDP pathologies (Table 1).
Sampling of patients and control individuals in the small geograph-
ical region of Flanders in Belgium further favoured the genetic
homogeneity of our study population.
We replicated association with the three TMEM106B SNPs from
the FTLD-TDP genome-wide association study and demonstrated
that the association is probably restricted to a 36kb genomic
region containing only the gene TMEM106B. The TMEM106B
SNPs, rs1990622 and rs1020004 were the most strongly asso-
ciated independent SNPs in the associated region. Carriers of
one or two copies of the TMEM106B protective alleles have a
30–50% reduced risk of developing FTLD. Although we did not
identify other independent associated SNPs, rs1990622 and
rs1020004 were in high linkage disequilibrium with 30 more
SNPs. The functional relevance of these SNPs to FTLD remains
unknown at present. However, the fact that they are all located
in or very close to TMEM106B, and that no other genes were
present in or near the associated region (Fig. 1), makes
TMEM106B the most likely candidate underlying the FTLD sus-
ceptibility. In silico prediction of the functional properties of the
32 SNPs anticipated the highest impact for rs3173615, a non-
synonymous SNP coding for a threonine (T) to serine (S) substi-
tution, though the predicted effect on protein function was
modest. The missense mutation is positioned at codon 185,
C-terminal of the transmembrane domain (codon 97–117).
Except for being a single-pass transmembrane protein, little is cur-
rently known about the function of TMEM106B, making it difﬁcult
to estimate the potential impact of amino acid substitutions on its
biological function. Analysis of protein conservation however indi-
cated that the T-residue at position 185 is highly conserved among
vertebrates.
In the original FTLD-TDP genome-wide association study, asso-
ciation with 7p21.3 was most pronounced in the subset of patients
carrying a GRN mutation. Based on this ﬁnding, it was hypothe-
sized that TMEM160B might act as a disease modiﬁer in GRN-
associated FTLD. We investigated a putative correlation of
rs1040002 and rs1990622 with onset age in the Flanders–
Belgian FTLD cohort but found no evidence for association.
Also, in an extended Flanders–Belgian FTLD founder family, char-
acterized by wide intrafamilial variability in onset age (Cruts et al.,
2006; Brouwers et al., 2007), the TMEM106B risk variants failed
Table 4 Genotypic association at the TMEM106B locus in
the Flanders–Belgian FTLD cohort
dbSNP ID Genotype Genotype
frequency
OR (95% CI) P-value
Patients Controls
rs1865567 AA 0.70 0.63 – –
AG 0.28 0.33 0.78 (0.56–1.10) 0.151
GG 0.00 0.04 0.40 (0.14–1.18) 0.096
rs1020004 TT 0.54 0.48 – –
TC 0.41 0.42 0.87 (0.65–1.17) 0.362
CC 0.06 0.10 0.49 (0.27–0.87) 0.014
rs1990622 TT 0.43 0.34 – –
TC 0.44 0.49 0.69 (0.51–0.93) 0.017
CC 0.13 0.18 0.55 (0.36–0.86) 0.009
Of the SNPs showing signiﬁcant allelic association, genotype frequencies in 297
patients and 595 control individuals are given. SNPs in bold are the replicated SNPs
form the FTLD-TDP genome-wide association study (Van Deerlin et al., 2010).
P-values and odds ratio (OR) with associated 95% conﬁdence interval (CI) were
calculated under an additive model using logistic regression models adjusted for
age and gender using the common genotype as reference. Signiﬁcant P-values are
in bold.
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carriers.
Further, we did not ﬁnd evidence that TMEM106B expression
correlated with disease. Although expression in Epstein-Barr virus
cell lines is known to be variable (Choy et al., 2008), the use of
lymphoblast cell lines allows the analysis of relatively larger sam-
ples sizes. In contrast, obtaining high-quality RNA from a signiﬁ-
cant number of brain samples is challenging. In our study we were
able to analyse brain samples from 11 patients with FTLD-TDP
and 12 control individuals. In this sample set we observed no
increased TMEM106B expression in patients with FTLD-TDP
compared with controls. Although our number of brain samples
was limited, it was in the same range as the original study who
found a positive correlation with TMEM106B expression in 25
brains (Van Deerlin et al., 2010). Expression analyses of larger
number of patient and control brains will be vital to resolve
whether or not TMEM106B pathogenesis is mediated by variable
gene expression.
Taken together, our study strongly supports TMEM106B as a risk
gene for FTLD though further research is needed to learn whether
T185S, variable gene expression or another mechanism contributes
to the disease biology driving the association of TMEM106B with
Figure 2 TMEM106B messenger RNA levels in lymphoblast cell lines and brain frontal cortex by disease status and genotype.
TMEM106B messenger RNA expression was measured by quantitative reverse-transcription polymerase chain reaction. (A) Relative gene
expression in lymphoblast cell lines from patients (n = 22) compared with control individuals (n = 26). (B) Relative gene expression in
lymphoblast cell lines from patients and control individuals pooled according to genotype at rs1990622. (C) Relative gene expression in
brain frontal cortex from FTLD-TDP patients (n = 11) compared with control individuals (n = 12). (D) Relative gene expression in brain
frontal cortex from patients and control individuals pooled according to genotype at rs1990622. In general, we found no evidence that
TMEM106B messenger RNA expression is increased in FTLD patients or that TMEM106B rs1990622 genotype is correlated with gene
expression. Circles = patients; squares = controls; horizontal lines = group mean.
814 | Brain 2011: 134; 808–815 J. van der Zee et al.FTLD. As other replication studies of TMEM106B are being
reported in geographically distinct populations, the extent of the
genetic contribution of TMEM106B to FTLD risk will become clear.
Interestingly, while our paper was under review, the principal
authors of the FTLD-TDP genome wide association study published
their observations that TMEM106B genotypes also seem to inﬂu-
ence the development of cognitive impairment in ALS patients,
further broadening the implications of the TDP-43 proteinopathy
spectrum that binds FTLD and ALS (Vass et al., 2010).
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